SCHEDULE: FMR LLC Boosts Stake in 10x Genomics to 10.8%

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 10.8% of 10x Genomics, Inc.'s Class A Common Stock as of December 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 12,696,254.11 shares of 10x Genomics, Inc. Class A Common Stock.
• This ownership represents 10.8% of the total outstanding Class A Common Stock.
• The reported beneficial ownership includes 892,772 shares of Class B Common Stock, which are convertible into Class A Common Stock on a 1:1 basis.
• These 892,772 Class B shares constitute 8.8579% of the outstanding Class B Common Stock.
• If all outstanding Class B Common Stock were converted to Class A, the reported ownership would represent 10.0324% of the outstanding Class A Common Stock.
• FMR LLC, a Delaware-organized parent holding company, and its subsidiaries (FIAM LLC, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, Strategic Advisers LLC) are the reporting entities.
• Abigail P. Johnson, as a U.S. citizen and a key figure in FMR LLC, is also a reporting person.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates a substantial and continued institutional investment by FMR LLC and its affiliates in 10x Genomics, Inc., which can be viewed as a vote of confidence. However, it is a routine ownership disclosure and does not contain new operational or financial performance data.

Positives

• Significant institutional investment from FMR LLC, indicating confidence in 10x Genomics, Inc.
• The holding company structure with various investment advisory subsidiaries suggests a diversified and professional investment approach.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder like FMR LLC can provide a level of confidence and stability, potentially attracting other investors.
• Management: Awareness of a large, active institutional shareholder may influence strategic decisions and corporate governance practices.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a significant beneficial ownership stake by FMR LLC and Abigail P. Johnson in 10x Genomics, Inc. While a substantial institutional holding can be a positive signal, the filing itself does not provide sufficient operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It confirms a large, stable institutional presence, suggesting a 'hold' position is appropriate for existing investors pending further fundamental analysis of the company's performance and outlook.

Keywords

10x Genomics, FMR LLC, Abigail P. Johnson, Class A Common Stock, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotechnology, Genomics, SEC Filing